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Abstract
Objective Erythropoietin (EPO) improves cardiac function
and induces neovascularisation in post-myocardial infarc-
tion heart failure. The aim of this study was to analyse
the association between the serum erythropoietin level and
coronary collateral development in patients with coronary
artery disease and chronic total occlusion.
Methods A total of 168 patients consisting of 117 with
coronary artery disease (CAD, (62 with chronic total occlu-
sion (CTO), 55 without CTO)) and 51 with healthy coronary
arteries were included in the study. The patients were as-
signed as coronary artery disease without CTO (group 0),
CAD with CTO (group 1: poor collateral development,
group 2: good collateral development) and normal coro-
nary arteries (group 3).
Results There was a significant positive correlation between
serum EPO levels and the Rentrop scores in angiography
(r = 0.243, p = 0.001). Similarly, a positive correlation was
found between serum EPO levels and the Syntax scores
(r = 0.253, p = 0.001). Echocardiography revealed a nega-
tive correlation between serum EPO levels and the cardiac
ejection fraction (r = –0.210, p = 0.006).
Conclusions Serum EPO is a useful biomarker for coronary
collateral development in patients with CTO.
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Introduction
Coronary collateral circulation is one of the important fac-
tors in preserving myocardium from ischaemic injury after
coronary occlusion. Studies have demonstrated that coro-
nary collaterals play a role in preserving myocardial func-
tion in case of an acute infarction [1, 2]. There is a signif-
icant variation in the degree of coronary collateral devel-
opment in patients with coronary artery disease (CAD) [3].
Erythropoietin (EPO) is an erythropoietic growth factor that
stimulates survival, proliferation, and differentiation of ery-
throid progenitor cells [4]. EPO improves cardiac function
and induces neovascularisation in post-myocardial infarc-
tion (MI) heart failure [5]. Also, many clinical studies have
implicated a functional significance of collateral arteries in
relation to preserving left ventricular function [6]. It is
a naturally occurring hormone secreted by the kidney and
stimulates haematopoiesis in the bone marrow, which reg-
ulates haematopoiesis. In addition to the haematopoietic
effect of EPO, recent studies in the literature corroborate
its anti-oxidative, anti-inflammatory and anti-apoptotic ef-
fects in protection against ischaemia-reperfusion injury [7].
In fact, many experimental studies have demonstrated that
EPO decreases myocardial and renal damage after hypoxic
insult, while on the other hand, there are also reports from
clinical studies about conflicting results [8, 9, 11].
In this study, we aimed to explore the association be-
tween the serum EPO level and coronary collateral devel-
opment in patients who had coronary artery disease with
chronic total occlusion (CTO), patients who had CAD with-
out CTO and in patients who did not have CAD.
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Materials and methods
Study population
A total of 168 consecutive patients were included in the
study, thus possible bias was avoided. Of the patients, 117
had CAD (61 ± 10 years) and 51 had healthy coronary ar-
teries (56 ± 10 years). Patients were assigned into CAD
without CTO (group 0), CAD with CTO (group 1: poor
collateral development, group 2: good collateral develop-
ment) and the normal coronary arteries (group 3). The
patients with Rentrop score 0 and 1 were identified as poor
collateral group, while patients with scores of 2 and 3 were
identified as the good collateral group. The baseline clinical
and biochemical characteristics of patients are presented in
Table 1.
Those patients who had associated haemolytic, hepatic
and renal diseases, and a history of coronary artery bypass
surgery were excluded. Written informed consent was ob-
tained from each subject, and the Institutional Ethics Com-
mittee approved the study protocol.
The study population was divided into patients who had
CAD (defined as visual diameter stenosis ≥30 %) and pa-
tients who did not have CAD. Patients who had CAD were
assigned into two groups: patients with and without total
occlusion. Patients with total occlusion were divided into





















Age (years) 61 ± 10 61 ± 11 61 ± 10 56 ± 10 NS
Male (within groups %) 74 79 84 75 NS
Diabetes mellitus (n) 22 8 14 14 NS
Dyslipidaemia (n) 33 15 19 27 NS
Smoking (n) 23 15 21 20 NS
Hypertension (n) 36 16 18 30 NS
Family history of CAD (n) 28 11 21 29 NS
Ejection fraction (%) 57.8 ± 8.3 57.4 ± 8.9 56 ± 11 61.5 ± 5 0.07
LDL (mg/dl) 112.4 ± 37.4 123.5 ± 34 117.2 ± 37.2 131.2 ± 31.9 NS
HDL (mg/dl) 38.9 ± 9.6 37.8 ± 11.1 37.9 ± 9.8 44.7 ± 11 0.003
Triglyceride (mg/dl) 168.9 ± 127.2 151.9 ± 84.3 166.7 ± 90.1 193.3 ± 103.5 NS
Total cholesterol (mg/dl) 186.2 ± 41 197 ± 47.6 188.2 ± 40 209.3 ± 40.2 0.03
Creatinine (mg/dl) 0.8 ± 0.1 0.9 ± 0.2 0.8 ± 0.2 0.8 ± 0.1 NS
Haemoglobin (mg/dl) 13.3 ± 1.5 13.5 ± 1.4 13.5 ± 2.0 13.4 ± 1.4 NS
BMI (kg/m2) 28 ± 5 28 ± 2 29 ± 2 27 ± 3 NS
Systolic BP (mm Hg) 129 ± 19 131 ± 15 133 ± 22 128 ± 23 NS
Diastolic BP (mm Hg) 78 ± 9 80 ± 8 81 ± 10 77 ± 9 NS
Data are given as mean ± SD or %
NS non-significant, CTO chronic total occlusion, CAD coronary artery disease, HDL high-density lipoprotein, LDL low-density lipoprotein,
BMI body mass index, BP blood pressure
two groups according to the Rentrop scoring of collateral
development and whether collateral development was good
or poor. Differences in EPO levels between the groups were
investigated.
In the CTO group (group 1 and 2) the average duration
of angina was 10.3 ± 4.7 months, there was history of MI
in 75.8 % (n = 47), and the possible duration of the CTO
was 6.5 ± 2.4 months. In 82 % of patients (n = 52), CTO
localisation was in the proximal portion.
Cardiac function was evaluated by transthoracic echocar-
diography (using the Vivid S5 machine, GE Healthcare).
Left ventricular ejection fraction (LVEF) was calculated us-
ing the modified Simpson method. Regional wall motion
was assessed using the 16-segment model as recommended
by the American Society of Echocardiography.
Blood samples were drawn from an antecubital vein to
measure EPO levels in all participants and subsequently
centrifuged at 730 x g for 10 min at +4 °C and then stored
at –20 °C until assayed. Serum EPO levels were deter-
mined by using standard enzyme-linked immunosorbent
assay (ELISA-EPO, Biomerica, Irvine, CA, USA).
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Coronary angiography and collateral development
grading
Coronary angiography was performed via the transfemoral
approach according to the Seldinger technique. In case of
significant lesions in femoral arteries, the angiography was
performed via a transradial approach according to Sones’
technique. Target lesions were evaluated both visually and
with quantitative coronary angiography by two experienced
interventional cardiologists. A minimum of three views for
the right coronary artery and five views for the left coronary
artery were recorded for each patient. CTO was defined as
complete occlusion of coronary artery flow for more than
three months. Coronary collateral flow to the infarct-related
artery was graded on baseline angiograms with the use of
4-degree qualitative classification proposed by Rentrop and
Cohen [1]: grade 0 – no visible filling of any collateral
channel; grade 1 – filling of the side branches of the oc-
cluded artery with no dye reaching the epicardial segment;
grade 2 – partial filling of the epicardial vessel; and grade
3 – complete filling of the epicardial vessel by collaterals.
The Syntax score was calculated for each coronary lesion
with a diameter stenosis of at least 50 % in vessels of at least
1.5 mm. The latest online version was used for the calcu-
lation of the SYNTAX score (http://www.SYNTAXscore.
com).
Statistical analysis
In this study, data were expressed as mean ± standard devia-
tion for continuous variables, and as counts and percentages
for categorical variables. Data were tested for normal dis-
tribution using the Kolmogorov-Smirnov test. The Mann-
Whitney U test was used to compare the EPO levels be-
tween the groups. As regards the categorical variables, dif-
ferences between the groups were examined using the Chi-
square test. Differences between the groups were tested
using one-way analysis of variance, followed by Tukey’s
post-hoc test. Correlations between variables were evalu-
ated using the Pearson or Spearman’s correlation analysis.
Values from 0 to 0.3 indicated weak, from 0.3 to 0.7 in-
dicated intermediate, and from 0.7 to 1.0 indicated strong
correlation. A p value <0.05 was considered statistically
significant. Statistical analyses were conducted with a com-
mercially available software package (SPSS version 16.0,
SPSS, Chicago, IL).
Results
The baseline clinical and laboratory characteristics of all
the study groups are summarised in Table 1. Patients in all
groups were of a similar age. There was no difference be-
tween the groups with respect to the traditional risk factors
for CAD, such as diabetes mellitus, dyslipidaemia, smok-
ing, and hypertension. Low-density lipoprotein, triglyc-
eride, creatinine, systolic blood pressure, diastolic blood
pressure, body mass index and haemoglobin values were
similar across all groups. There was a trend towards a dif-
ference in the LVEF; it was higher in the control group
than in the CAD groups, although this was not statistically
significant (p > 0.05).
High-density lipoprotein and total cholesterol values
were higher in the control group than in the other groups.
The serum EPO levels in patients with CTO (group 1 and
2) were significantly higher than in patients without CTO
(group 0 and 3) (98.88 mIU/ml vs. 76.96 mIU/ml, p =
0.005, Mann-Whitney test). The serum EPO level was sig-
nificantly higher, especially in the patient group with CTO
and developed collaterals (group 2: 112.4 ± 20.5 mIU/ml)
compared with the patients without CAD (group 3: 18.6 ±
2.0 mIU/ml) (p < 0.001). Differences between the other
groups were not statistically significant (p > 0.05). Fig. 1
shows the association of the logarithmic conversion of
plasma EPO levels across the groups.
There was a significant positive correlation between
serum EPO levels and the Rentrop scores in angiography
(r = 0.243, p = 0.001, Fig. 2). Similarly, a positive correla-
tion was found between serum EPO levels and the Syntax
scores (r = 0.253, p = 0.001, Fig. 3). Echocardiography
revealed a negative correlation between serum EPO levels
and the cardiac ejection fraction (r = –0.210, p = 0.006,
Fig. 4). The relationship between serum EPO level was
independent of haemoglobin levels and other variables.
In multiple linear regression analysis, independent pre-
dictors were investigated for increased serum EPO levels.
The Rentrop score was found to be an independent predictor
for increased serum EPO levels (beta = 38.576, p = 0.008,
model R2 = 0.112). Other parameters that analysed for in-
dependent predictors of serum EPO elevation are shown in
Table 2.
A serum EPO level of 22.3 mU/ml or higher in pa-
tients with developed collaterals predicts the development
of coronary collaterals with 61.3 % sensitivity and 58.9 %
specificity. Fig. 5 shows the receiver-operating characteris-
tic curve analysis graph regarding the association between
the serum EPO level and the collateral development.
Discussion
This purpose of this study was to ascertain whether a higher
serum EPO level is associated with a better coronary col-
lateral vessel grade in patients with CTO. We discovered
that the serum EPO level was significantly higher in CTO
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Fig. 1 Logarithmic relation-
ship of patient groups with
serum erythropoietin levels.
(Group 0: Coronary artery dis-
ease without total occlusion,
group 1: CTO with poor col-
lateral development (Rentrop
class I), group 2: CTO with
good coronary collateral de-
velopment (Rentrop II–III),
group 3: normal coronary arter-
ies, logerythropoietin: Logarithmic
conversion of plasma erythro-
poietin levels)
Fig. 2 There was a significant
positive correlation between
serum EPO levels and the Ren-
trop scores in angiography (r =
0.243, p = 0.001)
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Fig. 3 A positive correlation
was found between serum EPO
levels and the Syntax scores (r =
0.253, p = 0.001)
Fig. 4 Echocardiography re-
vealed a negative correlation
between serum EPO levels and
the cardiac ejection fraction (r =
–0.210, p = 0.006)
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Table 2 Multiple linear regression analysis (method = enter) for the independent predictors of the increased serum EPO levels (model R2 =
0.112)
Variables Beta 95 % CI p value
Rentrop score 38.576 10.098, 67.053 0.008
Ejection fraction –1.752 –4.125, 0.621 0.147
Creatinine level 42.551 –66.312, 151.414 0.441
Hypertension –26.006 –68.907, 16.896 0.233
Smoking –2.923 –45.355, 39.508 0.892
Family history of CAD 2.183 –37.326, 41.691 0.913
Gender –4.399 –53.165, 44.367 0.859
Age 1.707 –0.309, 3.723 0.09
Diabetes mellitus –1.552 –45.772, 42.667 0.94
Hyperlipidaemia 9.843 –30.342, 50.028 0.629
Syntax score –0.985 –3.046, 1.076 0.347
CAD Coronary artery disease
Fig. 5 ROC analysis graph on the association between serum EPO
level and coronary collateral development. (AUC area under the curve,
green line reference line)
patients who had a better coronary collateral vessel grade.
Moreover, the relationship between serum EPO level and
collateral grade was independent of haemoglobin levels and
other variables.
It is clear that well-developed collaterals are associated
with a reduced mortality according to the pooled analysis
of the 12 studies, including 6529 patients [10]. Coronary
collateral vessels compensate for significant coronary arte-
rial occlusion by supplying extra blood for myocardial sal-
vage in the ischaemic region [10]. It has also been demon-
strated that EPO improves cardiac function independent of
the haemoglobin level. In our study we found the serum
EPO level was positively associated with coronary collat-
eral development while EPO was independently related to
the Syntax score in patients with CTO. Induction of neovas-
cularisation [5] and protection against ischaemic vascular
injury are proposed to be the main mechanism that provides
these beneficial effects of EPO [9].
Naimuchi et al. [12] investigated whether higher serum
EPO level in patients with acute MI subjected to success-
ful primary percutaneous coronary intervention (PCI) could
predict a smaller infarct size determined by the release of
creatine kinase. They found that a high endogenous EPO
level could predict a smaller infarct size in patients with
acute MI subjected to successful primary PCI. They at-
tributed these favourable effects of EPO to the induction
of new capillary formation and correction of endothelial
dysfunction [4, 5, 13]. In this present study, serum EPO
level was found to be significantly higher in patients with
a better coronary collateral vessel grade. Although these
findings suggested a net effect of EPO on angiogenesis, the
effect of EPO on arteriogenesis remained unclear. These
two processes in neovascularisation differ in certain impor-
tant aspects. Angiogenesis develops in response to hypoxia,
but arteriogenesis is related to smooth muscle cell prolifer-
ation and endothelial function [14].
Vascular smooth muscle cells have been found to express
EPO receptors [15, 16]. EPO was shown to increase DNA
replication and cellular growth through these receptors and
thus behaves as a vascular growth factor [17, 18]. In the
present study, although we did not evaluate the causative
mechanisms, we found that the degree of coronary collateral
vessels was better in patients with higher serum EPO levels.
This finding is in concordance with the results of the other
studies, which suggest a potential beneficial effect of EPO
on arteriogenesis.
Erythropoietin has been found to improve cardiac func-
tion and symptoms in patients with chronic heart failure
(CHF) [19]. Although it is argued that these beneficial
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effects of EPO in patients with CHF are related to the cor-
rection of anaemia, EPO has also been shown to improve
cardiac function independent of the haemoglobin level [4,
13]. However, Guo et al. [20] reported that EPO levels
might successfully predict the prognosis of CHF, and serum
EPO expression played an important role in the progression
of CHF. These findings indicate that neurohormonal acti-
vation and inflammation are the clinical responses to late
CHF. Therefore, determination of serum EPO expression is
clinically significant to predict the development, outcome
and prognosis of CHF. Tabary et al. [21] found that peri-
operative exogenous EPO infusion could not improve the
ventricular function and wall motion index in the immediate
weeks after coronary artery bypass graft surgery.
Sahinarslan et al. [22] found that the serum EPO level
was positively related to the Rentrop score in patients with
stable angina pectoris. Multivariate analysis revealed that
serum EPO level was independently related to well-devel-
oped coronary collaterals. Similarly, Xu et al. [23] reported
that increased serum EPO was one of the independent pre-
dictors of good collateral development (odds ratio 1.31,
p = 0.025). Moreover the study showed a significantly
positive correlation between serum EPO and vascular en-
dothelial growth factor (VEGF) levels (r = 0.96, p < 0.001).
Westenbrink et al. showed 4.5-fold increase in myocardial
expression of VEGF with EPO treatment, which was pos-
itively correlated with neovascularisation [5]. Our study
demonstrated that the endogenous serum EPO level could
be a potentially important biomarker in patients with CTO.
The presence of CTO in the groups had a positive relation-
ship with collateral grade. The pressure gradient leading to
shear stress in primitive collateral vessels may be higher in
case of total occlusion of the epicardial artery [24].
Conflicting results have been reported regarding the use
of EPO for treatment. Zafiriou et al. [25] recently re-
ported that repetitive, moderate-dose EPO treatment en-
hanced the proliferation of EPO-responsive myosin heavy
chain-expressing cells (EMCs), which as a result enabled
the preservation of post-ischaemic cardiac function in the
adult heart. EPO administration following MI increased
EMCs and preserved cardiac function. However, Kim et al.
[26] showed that patients who were at increased risk of
developing acute kidney injury after undergoing complex
valvular heart surgery did not get renal protection from in-
travenous administration of 300 IU/kg of EPO.
In conclusion, our findings suggest that a higher serum
EPO level is associated with better coronary collateral de-
velopment in patients with CTO. Circulatory EPO may be
a useful biomarker for coronary collateral development and
a potential target for therapeutic angiogenesis in patients
with CTO. Further studies are needed to determine the im-
pact of EPO on collateral vessel development and the po-
tential underlying mechanisms.
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